Stocks and Investing
Stocks and Investing
Fri, October 18, 2019
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
Thu, October 17, 2019
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
Matt Miksic Maintained (ABT) at Buy with Increased Target to $98 on, Oct 17th, 2019
Matt Miksic of Credit Suisse, Maintained "Abbott Laboratories" (ABT) at Buy with Increased Target from $95 to $98 on, Oct 17th, 2019.
Matt has made no other calls on ABT in the last 4 months.
There are 3 other peers that have a rating on ABT. Out of the 3 peers that are also analyzing ABT, 0 agree with Matt's Rating of Hold.
These are the ratings of the 3 analyists that currently disagree with Matt
- Jayson Bedford of "Raymond James" Maintained at Buy with Decreased Target to $90 on, Monday, October 14th, 2019
- Joanne Wuensch of "BMO Capital" Maintained at Buy with Increased Target to $94 on, Thursday, July 18th, 2019
- David Lewis of "Morgan Stanley" Maintained at Buy with Increased Target to $93 on, Tuesday, July 16th, 2019
Contributing Sources